SUNNYVALE, Calif., Feb. 10, 2014 /PRNewswire/ -- Miramar Labs®, Inc., a leading medical device manufacturer and maker of the miraDry® System, today announced the appointment of R. Michael Kleine as its new president, chief executive officer and a member of its board of directors. Mr. Kleine will succeed Darrell Zoromski, the company's current president and CEO, who had previously announced his intent to step down in order to spend more time with his family. Mr. Zoromski played an active role in the CEO search and will continue to support the company in the coming months to ensure a smooth leadership transition.
Mr. Zoromski joined Miramar Labs in 2008 and under his leadership the company introduced miraDry into Japan and completed their pivotal clinical trial leading to FDA clearance for the miraDry System in 2011. He also oversaw the U.S. launch and commercialization of the technology in the following year. Since that time, more than 20,000 miraDry procedures have been performed to date across North America and Asia Pacific.
"It has been extremely rewarding to help grow the company to its current state and the time is now ideal to transition it to a new leader. Not only does Mr. Kleine have nearly two decades of experience in C-suite positions in the healthcare industry, but his reputation and proven track record in commercializing new technologies in the U.S. is ideal for taking Miramar to the next level," said Mr. Zoromski. "I'm very pleased he is joining the team."
"We would like to thank Darrell for his 5 years of service with Miramar Labs. In his time with Miramar Labs he has led the company to achieve very significant milestones from FDA clearance to commercialization in North America and Asia Pacific," said Mark Deem, Co-founder and Chairman of the Board for Miramar Labs. "Those milestones have allowed the Board to attract someone of Mike's caliber. We believe he has the experience necessary to drive Miramar's growth and continued success."
Prior to joining Miramar Labs, Mr. Kleine was most recently the CEO of EndoGastric Solutions (EGS) and will continue to serve as its Chairman of the Board. During Mr. Kleine's time at EGS he strengthened the foundation of the company by completing two level one randomized clinical trials, prioritized R&D initiatives and pipeline, and greatly increased that company's involvement and visibility with major academic institutions and medical societies. He also served as president and CEO at Biosensors International Group, Ltd. Under his leadership, product revenue increased by threefold and Mr. Kleine was awarded the prestigious MAXA award for excellence in manufacturing. He also held leadership positions at Terumo Medical Corporation, MicroVention, Inc., Pharos, LLC, and Thermo Cardiosystems, Inc.
"Although I was initially approached to join Miramar Labs' Board of Directors, I jumped at the opportunity to take a more active role in growing and driving long-term performance of the company when I learned of Mr. Zoromski's decision to step down," said Mr. Kleine. "It's an exciting time to join Miramar Labs. Since the launch of the miraDry System, the company has gained a strong foothold in North America and Asia. There is significant interest in finding a lasting solution for chronic underarm sweat that is oftentimes embarrassing. With the recent CE mark approval, the company is poised to expand rapidly in Europe."
The miraDry System delivers energy non-invasively to the area under the arm where sweat glands reside, creating localized heat to destroy and eliminate those glands. Since sweat glands do not regenerate, results are lasting. The treatment is very effective and provides high patient satisfaction. On average, patients see more than 80 percent reduction in underarm sweat and report more than 90 percent satisfaction with the procedure results.
For more information, visit the miraDry website at www.miraDry.com, or follow miraDry on Facebook/miraDry and Twitter @miraDry.
About Miramar Labs:
Founded in 2006, Miramar Labs is a privately owned medical device company dedicated to bringing the next generation energy modality to the field of dermatology. Miramar Labs is the tenth company created by The Foundry, a leading medical device incubator based in Menlo Park, California. Supported by rigorous clinical research, Miramar Labs is focused on addressing medical conditions for which there are significant unmet clinical needs. The company's first priority is the treatment of excessive underarm sweat, a medical condition that significantly affects the quality of life of millions of people. Physicians and patients are encouraged to visit www.miradry.com for additional information about Miramar Labs.
SOURCE Miramar Labs, Inc.